Stocks · News reference
Wells Fargo analyst Tianqi Hang initiates coverage on Design Therapeutics (NASDAQ:DSGN) with a Overweight rating and announces Price Target of $26.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
U.S. stock futures mostly lower, Nasdaq 100 down 0.3%. Marvell Technology shares fall 7.6% after beating estimates, other stocks also drop in pre-market.
Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.34) by 5.88 percent. This is a 5.88 percent increase over losses of $(0.34) per share
Filed: 2026-08-03 AccNo: 0001193125-26-329570 Size: 489 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits